Results 191 to 200 of about 593,778 (297)
ABSTRACT Background Ischemic stroke, a major cause of mortality and long‐term disability, results from the abrupt cessation of cerebral blood flow due to vascular occlusion or rupture. Icosapent Ethyl (EPA‐EE), approved for hypertriglyceridemia, has anti‐inflammatory and antithrombotic properties that may lessen ischemic damage.
Mitra Mahmoudi Meymand +5 more
wiley +1 more source
AI-assisted VMAT planning incorporating deep learning-based dose prediction for head and neck cancer: feasibility of quality standardization and human intervention for irregular cases. [PDF]
Tomori S, Narazaki K, Tasaka S.
europepmc +1 more source
ABSTRACT Objective Early risk stratification may support clinical decision‐making in spontaneous intracerebral hemorrhage (ICH). We aimed to develop and internally validate HAGIV, a score integrating frequency of imaging markers (FIM), a time‐adjusted non‐contrast computed tomography (CT) metric of hematoma expansion, with established predictors for 90‐
Lei Song +10 more
wiley +1 more source
Importance of Standardizing Laboratory Medicine in a Super-aging Society. [PDF]
Kim S, Cho CI, Yun YM.
europepmc +1 more source
ABSTRACT Background Factors associated with relapse course and disability in myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) remain incompletely understood. Objectives To identify clinical and modifiable factors associated with relapse and disability in MOGAD. Methods In this ambispective multicentre cohort study using data from
Yingtao Wang +23 more
wiley +1 more source
From study design to executable code: automating target trial emulation with large language models. [PDF]
Kim H, Kim M, Kim S, You SC.
europepmc +1 more source
Digital Cognitive Testing in Mitochondrial Disease: Validity and Challenges for Clinical Trial Use
ABSTRACT Background Primary mitochondrial disease is a group of genetic disorders caused by pathogenic variants in nuclear or mitochondrial DNA, often resulting in progressive neurodegeneration and cognitive decline. Current management is primarily supportive, though recent research offers hope for disease‐modifying treatments in the future.
Oksana Pogoryelova +9 more
wiley +1 more source
The Metaproteomics Initiative: five years of community-driven progress. [PDF]
Van Den Bossche T +23 more
europepmc +1 more source
ABSTRACT Objective Building on our prior Behavioral Risk Factor Surveillance System analysis identifying adults aged 18–39 as the primary driver of the national increase in self‐reported cognitive disability, we examined factors associated with this rise using 2013–2024 U.S. BRFSS data. Methods We analyzed U.S.
Adam de Havenon +9 more
wiley +1 more source
Quantitative Ultrasound Imaging and Artificial Intelligence in Neonatal Echocardiography: Methodological Advances, Reproducibility Challenges, and Computational Perspectives. [PDF]
Nikolaou AI +6 more
europepmc +1 more source

